44-6 Techno 10-ro Yuseong HQ : +82-42-861-4551 info@genomictree.com

Office Address

44-6 Techno 10-ro Yuseong Daejeon South Korea

Phone Number

HQ : +82-42-861-4551

Early Tect : +82-1522-0474

Email Address



EarlyTect (R) is the promise of Genomictree to keep your tomorrow healthy through early detection of cancer.

EarlyTect® Colon Cancer

Colorectal cancer (CRC) screening can effectively reduce disease-related mortality by detecting CRC at earlier stages. Therefore, early detection of CRC has emerged as an important global issue to reduce its high mortality. Currently, colonoscopy is the most accurate screening method for early diagnosis of CRC. However, its compliance rate remains very low due to its invasiveness, dietary restriction requirement, and extensive bowel preparation. Although noninvasive fecal immunochemical tests (FIT) for hemoglobin in stool are available, their sensitivities are relatively low in detecting stage I CRC. Thus, developing highly accurate CRC screening method using molecular biomarkers for people who are reluctant to participate in colonoscopy examination is urgently needed for early detection of CRC.

Higi Medical Costs

Cancer Mortality Rate ranked “Second” in the World

About 60% of Patients are Detected at “Late Stage”

Average Treatment Cost per patient : Up to USD 150,000 (US), up to USD 30,000 (South Korea)

Survival Rate & Treatment Cost

Current Screening Tools for CRC Early Detection

Colonoscopy (Gold Standard)

  • High Invasiveness, Inconveniences
  • Low participation rate due to bowel preparation (Worldwide average of less than 30%)


  • Low sensitivity to early CRC (less than 50%) and polyps (≥ 1.0 cm; less than 20%)

Approbed by MFDS (18-593)

This test is a real-time PCR test that measures methylated syndecan-2 (SDC2) DNA using human fecal. Abnormal methylation of the syndecan-2 biomarker in colorectal cancer tissues is observed more than 95% regardless of the stage and is not observed in normal colorectal tissues. This indicates that the presence of methylated syndecan-2 DNA has a significant association with the incidence of colorectal neoplasia. It has been proven to be able to diagnose colorectal cancer with 90% sensitivity and 90% specificity, and 89% sensitivity for early stages (0-II) in a pivotal trial on 585 subjects at Yonsei University Severance Hospital and Severance Check-up Center.